Resistance Reporter > Editorial Advisory Board
Editorial Advisory Board Biographies and Disclosures
Note: Resistance Reporter is supported by an independent educational grant from Virco Lab, Inc and is produced by Visionary Health Concepts. Virco has provided website support to house this independent program for providers. Questions: info@resistancereporter.com.
Dan Kuritzkes, MD
Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University in 1978, and his MD from Harvard Medical School in 1983. He completed his clinical and research training in internal medicine and infectious disease at Massachusetts General Hospital, and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center in 1990. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Director of AIDS Research, Brigham & Women's Hospital. He is also Head of the Section of Retroviral Therapeutics for the Harvard Division of AIDS, and Principal Investigator of the Harvard AIDS Clinical Trials Unit.
Dr. Kuritzkes has authored nearly 200 articles, chapters, and reviews on antiretroviral therapy and on the problem of drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and is a member of the International AIDS Society-USA panel on HIV drug resistance and resistance testing. He has served on numerous NIH committees and editorial boards, and currently chairs the AIDS Clinical Trials Group Scientific Agenda Steering Committee, in addition to serving as Vice Chair of the ACTG Executive Committee. Dr. Kuritzkes also is an Associate Editor of the Journal of Infectious Diseases and Chair, Board of Directors of the HIV Medicine Association. His research interests focus on antiretroviral therapy and drug resistance.
Disclosure: Abbott: consultant, honoraria; Anormed: consultant, honoraria; Avexa: consultant, honoraria; Bayer: grant support, consultant, honoraria; Biogen Idec: consultant; Boehringer Ingleheim: grant support, honoraria, consultant; Bristol-Myers Squibb: grant support, honoraria, consultant; Gilead: consultant, honoraria; GlaxoSmithKline: consultant, honoraria, grant support; Human Genome Sciences: grant support, honoraria; Merck: consultant, honoraria, grant support; Monogram Biosciences: consultant, honoraria; Panacos: consultant, honoraria; Pfizer: consultant, honoraria; Roche/Trimeris: grant support, consultant, honoraria; Schering-Plough: consultant, grant support, grant support; Tanox : consultant; Tibotec: consultant, grant support; VirXsys: consultant, honoraria
Rodger MacArthur, MD
Dr. Rodger D. MacArthur currently is a Professor of Medicine in the Division of Infectious Diseases at Wayne State University, and Director of HIV/AIDS Clinical Research at the Detroit Medical Centre, Detroit, USA. He graduated from Northwestern University, Chicago in 1977. He received an MA from Columbia University, New York, in 1979 and his MD from the University of Illinois College of Medicine, Chicago, in 1983. Dr. MacArthur completed a residency in Internal Medicine at Case Western Reserve University (University Hospitals and Cleveland VA Medical Center) in 1986 and a fellowship in Infectious Diseases at the Johns Hopkins Hospital in Baltimore in 1988.
Dr MacArthur has received numerous awards and honors, including a Wayne State University School of Medicine Teaching Award in 2004. He has served as chair or co-chair of several NIH/NIAID-sponsored clinical trials, including the recently completed CPCRA 058 FIRST trial (The Lancet, 16 December 2006). His current research interests are in the field of HIV resistance and antiretroviral effectiveness.
Dr MacArthur has been widely published; many journal articles, abstracts, book chapters on HIV/AIDS treatment, drugs and resistance, have been credited to him. Dr. MacArthur serves on the Scientific Review Committee of the Ontario HIV Treatment Network, and chairs the genotyping working group for the OHTN Cohort Study. He is a journal reviewer for The Lancet, Academic Emergency Medicine, and the Journal of Infectious Diseases, among others.
Disclosure: Abbott Laboratories: speakers' bureau; grant support; Boehringer Ingelheim: grant support; Gilead: speakers' bureau; GlaxoSmithKline: speakers' bureau, grant support; Pfizer: speakers' bureau, grant support; Roche Laboratories: speakers' bureau; Virco Lab, Inc: speakers' bureau.
Paul Sax, MD
Dr. Paul E. Sax is Clinical Director of the Division of Infectious Diseases and the HIV Program at Brigham and Women's Hospital (BWH), Boston. He has been on the faculty at Harvard Medical School since 1992, where he is currently an Associate Professor of Medicine. Dr. Sax received his MD from Harvard Medical School in 1987. He served his residency in Internal Medicine at BWH, while continuing his postdoctoral education with a fellowship in the Infectious Disease Unit of Massachusetts General Hospital. Dr. Sax is board certified in Internal Medicine and Infectious Diseases. He is Editor-in-Chief of AIDS Clinical Care, is on the peer review board of the HIV/AIDS Section of UpToDate, and is the HIV disease section editor for Infectious Diseases Special Edition. Dr. Sax is also on the core faculty of the International AIDS Society - USA and the New England AIDS Education and Training Center.
In addition to his clinical and teaching work, Dr. Sax is actively involved in HIV research. Ongoing areas of research interest include clinical trials of antiretroviral therapies, cost-effectiveness of management strategies for HIV, toxicity of antiretroviral treatment, and identification, treatment and outcome of primary HIV infection.
He is presently the principal investigator at the BWH AIDS Clinical Trials Unit, and is a member of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Research Group. Dr. Sax has authored and co-authored many HIV-related published reports, abstracts, reviews and clinical communications. He was awarded the Edward H Kass Award in Clinical Excellence in 1993, the Harvard-Longwood Infectious Disease Fellowship Award in Clinical Teaching in 1997, and a Distinguished Faculty Resident Mentoring Award in 2003.
Disclosure: Abbott: consultant, honoraria; Bristol-Myers Squibb: consultant, honoraria, grant support; Gilead: consultant, honoraria; GlaxoSmithKline: consultant, honoraria; Merck: honoraria, grant support; Pfizer: grant support; Tibotec: honoraria; Virco: honoraria.
Joseph J. Eron, Jr., MD
Dr. Eron is a Professor of Medicine at the University of North Carolina at Chapel Hill. He has been the Director of the UNC AIDS Clinical Trials Unit for 4 years and was the Associate Director for seven years prior to becoming the Director. He is also the Director of the UNC Center for AIDS Research Clinical Core and the Associate Director of the General Clinical Research Center at UNC. Dr. Eron received his medical degree at Harvard Medical School and completed his Infectious Diseases training under Martin Hirsch MD at Massachusetts General Hospital. His research activities included the design and implementation of antiretroviral treatment trials, the study of Acute HIV Infection and the implementation of an observational HIV Clinical/Research database. Dr. Eron an ex officio member of the Optimization of Antiretroviral Therapy (OpART) Committee of the ACTG which aims to develop new treatment strategies to limit the replication of HIV-1, further understand HIV-1 resistance to antiretroviral therapy and optimize use of resistance assays, develop and validate laboratory techniques, and improve and optimize study design.
Disclosure: Bristol-Myers Squibb: consultant, speaker's bureau; Gilead: speaker's bureau; GlaxoSmithKline: consultant; Merck: grant support (UNC-CH); Panacos: grant support (UNC-CH); Roche Laboratories: consultant, speaker's bureau; Tibotec Therapeutics: consultant; Virco Lab, Inc: consultant, speaker's bureau.
Lillian Thiemann (HIV community-faculty)
Lillian Thiemann is the co-founder and President of Visionary Health Concepts, a community-based health and medical education company specializing in HIV and hepatitis and the co-founder of the award-winning Women's HIV Collaborative of New York (www.womenscollaborative.com). Utilizing multimedia programs, Visionary Health Concepts seeks to be a bridge of understanding between healthcare providers and consumers by promoting increased communication on complex topics and facilitating an individualized care model. For more information or to view other VHConcepts' independent educational programming (CME and non-accredited for providers and consumers), please visit www.freehivinfo.com and www.freehepatitisinfo.com.
Disclosure: Lillian Thiemann has no relationships to report.
